BHA‐CS: A novel cognitive composite for Alzheimer's disease and related disorders. Issue 1 (21st June 2020)

• Record Type: Journal Article
• Authors: Tsoy, Elena; Erlhoff, Sabrina J.; Goode, Collette A.; Dorsman, Karen A.; Kanjanapong, Suchanan; Lindbergh, Cutter A.; La Joie, Renaud; Strom, Amelia; Rabinovici, Gil D.; Lanata, Serggio C.; Miller, Bruce L.; Tomaszewski Farias, Sarah E.; Kramer, Joel H.; Rankin, Katherine P.; Possin, Katherine L.
• Is Part Of: Alzheimer's & dementia. Volume 12:Issue 1(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-06-21
• Subjects: Alzheimer disease -- computerized cognitive assessment -- dementia -- early detection -- neuropsychology -- psychometrics; Alzheimer's disease -- Periodicals; Alzheimer's disease -- Diagnosis -- Periodicals; Dementia -- Periodicals; Dementia -- Diagnosis -- Periodicals; 616.831
• DOI: 10.1002/dad2.12042
• Languages: English
• ISSNs: 2352-8729

Abstract

Abstract: Introduction: Composite scores based on psychometrically rigorous cognitive assessments are well suited for early diagnosis and disease monitoring. Methods: We developed and cross‐validated the Brain Health Assessment‐Cognitive Score (BHA‐CS), based on a brief computerized battery, in 451 cognitively normal (CN) and 399 cognitively impaired (mild cognitive impairment [MCI] or dementia) older adults. We investigated its long‐term reliability and reliable change indices at longitudinal follow‐up (N = 340), and the association with amyloid beta (Aβ) burden in the CN subgroup with Aβ positron emission tomography (N = 119). Results: The BHA‐CS was accurate at detecting cognitive impairment and exhibited excellent long‐term stability. Reliable decline over one year was detected in 75% of participants with dementia, 44% with MCI, and 3% of CN. Among CN, the Aβ‐positive group showed worse longitudinal performance on the BHA‐CS compared to the Aβ‐negative group. Discussion: The BHA‐CS is sensitive to cognitive decline in preclinical and prodromal neurodegenerative disease.